Skip to main content

Advertisement

SpringerLink
Log in

Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Purpose

The purpose of this study was to evaluate treatment response and complications of transarterial chemoembolization using drug-eluting beads loaded with irinotecan (DEBIRI) in patients with liver metastases from uveal melanoma (UM).

Materials and Methods

Patients treated with DEBIRI (n = 14) were retrospectively analyzed regarding overall survival, compared to patients (n = 14) treated with intravenous dacarbazine (DTIC). Median overall survival was calculated from time of diagnosis of metastatic disease (OS1) and start of treatment (OS2). Radiological response for DEBIRI was assessed according to RECIST 1.1 on contrast-enhanced computed tomography (CT), obtained 1.5 months (range 1.2–3.7) post treatment. Major complications of DEBIRI were defined according to the Society of Interventional Radiology classification for complications by outcome.

Results

In the DEBIRI group, OS1 was 14.8 months (range 3.9–47.5), and OS2 was 9.4 months (range 1.7–39). Further, 11/13 (84.6 %) of these patients had progressive disease on first follow-up CT and new lesions were seen in nine. There were 12 major complications in nine patients, possibly including one case of mortality due to disseminated intravascular coagulation (DIC).

Conclusion

For patients with liver metastases from UM, the effect on overall survival of DEBIRI alone is questionable. Compared to previous reports, the response rate of DEBIRI was poor, with new liver lesions observed in the majority of patients. Major complications possibly included one case of DIC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology. 2011;118(9):1881–5.

    Article  PubMed  Google Scholar 

  2. Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Biggeri A, Crocetti E, et al. Incidence of uveal melanoma in Europe. Ophthalmology. 2007;114(12):2309–15.

    Article  PubMed  Google Scholar 

  3. Cerbone L, Van Ginderdeuren R, Van den Oord J, Fieuws S, Spileers W, Van Eenoo L, et al. Clinical presentation, pathological features and natural course of metastatic uveal melanoma, an orphan and commonly fatal disease. Oncology. 2014;86(3):185–9.

    Article  PubMed  Google Scholar 

  4. Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK. Metastatic melanoma from intraocular primary tumors: the Southwest Oncology Group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol. 1998;21(6):568–72.

    Article  CAS  PubMed  Google Scholar 

  5. Woodman SE. Metastatic uveal melanoma: biology and emerging treatments. Cancer J. 2012;18(2):148–52.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Bedikian AY, Legha SS, Mavligit G, Carrasco CH, Khorana S, Plager C, et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76(9):1665–70.

    Article  CAS  PubMed  Google Scholar 

  7. Patel K, Sullivan K, Berd D, Mastrangelo MJ, Shields CL, Shields JA, et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res. 2005;15(4):297–304.

    Article  PubMed  Google Scholar 

  8. Huppert PE, Fierlbeck G, Pereira P, Schanz S, Duda SH, Wietholtz H, et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol. 2010;74(3):e38–44.

    Article  CAS  PubMed  Google Scholar 

  9. Vogl T, Eichler K, Zangos S, Herzog C, Hammerstingl R, Balzer J, et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol. 2007;133(3):177–84.

    Article  CAS  PubMed  Google Scholar 

  10. Gupta S, Bedikian AY, Ahrar J, Ensor J, Ahrar K, Madoff DC, et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol. 2010;33(5):474–80.

    Article  PubMed  Google Scholar 

  11. Edelhauser G, Schicher N, Berzaczy D, Beitzke D, Hoeller C, Lammer J, et al. Fotemustine chemoembolization of hepatic metastases from uveal melanoma: a retrospective single-center analysis. Am J Roentgenol (AJR). 2012;199(6):1387–92.

    Article  Google Scholar 

  12. Brown DB, Nikolic B, Covey AM, Nutting CW, Saad WE, Salem R, et al. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol (JVIR). 2012;23(3):287–94.

    Article  Google Scholar 

  13. Yamamoto A, Chervoneva I, Sullivan KL, Eschelman DJ, Gonsalves CF, Mastrangelo MJ, et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology. 2009;252(1):290–8.

    Article  PubMed  Google Scholar 

  14. Eldredge-Hindy H, Ohri N, Anne PR, Eschelman D, Gonsalves C, Intenzo C et al. Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma: clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography. Am J Clin Oncol. 2014 (Epub ahead of print).

  15. Gonsalves CF, Eschelman DJ, Sullivan KL, Anne PR, Doyle L, Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. Am J Roentgenol (AJR). 2011;196(2):468–73.

    Article  Google Scholar 

  16. Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, et al. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. RoFo: Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2014;186(10):937–44.

    Article  CAS  PubMed  Google Scholar 

  17. Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS. Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol. 2014;109(5):434–9.

    Article  PubMed Central  PubMed  Google Scholar 

  18. Yamamoto M, Zager JS. Isolated hepatic perfusion for metastatic melanoma. J Surg Oncol. 2014;109(4):383–8.

    Article  PubMed  Google Scholar 

  19. Olofsson R, Cahlin C, All-Ericsson C, Hashimi F, Mattsson J, Rizell M, et al. Isolated hepatic perfusion for ocular melanoma metastasis: registry data suggests a survival benefit. Ann Surg Oncol. 2014;21(2):466–72.

    Article  CAS  PubMed  Google Scholar 

  20. Carter S, Martin RC II. Drug-eluting bead therapy in primary and metastatic disease of the liver. HPB (the official journal of the International Hepato Pancreato Biliary Association). 2009;11(7):541–50.

    Article  Google Scholar 

  21. Lewis AL, Dreher MR. Locoregional drug delivery using image-guided intra-arterial drug eluting bead therapy. J Control Release (official journal of the Controlled Release Society). 2012;161(2):338–50.

    Article  CAS  Google Scholar 

  22. Tang Y, Taylor RR, Gonzalez MV, Lewis AL, Stratford PW. Evaluation of irinotecan drug-eluting beads: a new drug-device combination product for the chemoembolization of hepatic metastases. J Control Release (official journal of the Controlled Release Society). 2006;116(2):e55–6.

    Article  CAS  Google Scholar 

  23. Fiorentini G, Aliberti C, Del Conte A, Tilli M, Rossi S, Ballardini P, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo. 2009;23(1):131–7.

    PubMed  Google Scholar 

  24. Venturini M, Pilla L, Agostini G, Cappio S, Losio C, Orsi M, et al. Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients. J Vasc Interv Radiol (JVIR). 2012;23(7):937–41.

    Article  Google Scholar 

  25. Valpione S, Aliberti C, Parrozzani R, Bazzi M, Pigozzo J, Midena E, et al. A retrospective analysis of 141 patients with liver metastases from uveal melanoma: a two-cohort study comparing transarterial chemoembolization with CPT-11 charged microbeads and historical treatments. Melanoma Research. 2014 (epub ahead of print).

  26. Sacks D, McClenny TE, Cardella JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol (JVIR). 2003;14(9 Pt 2):S199–202.

    Article  Google Scholar 

  27. Eschelman DJ, Gonsalves CF, Sato T. Transhepatic therapies for metastatic uveal melanoma. Semin Interv Radiol. 2013;30(1):39–48.

    Article  Google Scholar 

  28. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97(2):465–75.

    Article  PubMed  Google Scholar 

  29. Leyvraz S, Piperno-Neumann S, Suciu S, Baurain JF, Zdzienicki M, Testori A, et al. Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial. Ann Oncol (official journal of the European Society for Medical Oncology/ESMO). 2014;25(3):742–6.

    Article  CAS  Google Scholar 

  30. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol (official journal of the American Society of Clinical Oncology). 2007;25(13):1753–9.

    Article  Google Scholar 

  31. Hayano K, Fuentes-Orrego JM, Sahani DV. New approaches for precise response evaluation in hepatocellular carcinoma. World J Gastroenterol (WJG). 2014;20(12):3059–68.

    Article  Google Scholar 

  32. Martin RC, Howard J, Tomalty D, Robbins K, Padr R, Bosnjakovic PM, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Interv Radiol. 2010;33(5):960–6.

    Article  CAS  Google Scholar 

  33. Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G. Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res. 2013;33(5):2077–83.

    CAS  PubMed  Google Scholar 

  34. Richardson AJ, Laurence JM, Lam VW. Transarterial chemoembolization with irinotecan beads in the treatment of colorectal liver metastases: systematic review. J Vasc Interv Radiol (JVIR). 2013;24(8):1209–17.

    Article  Google Scholar 

  35. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

    CAS  PubMed  Google Scholar 

  36. Clark TW. Complications of hepatic chemoembolization. Semin Interv Radiol. 2006;23(2):119–25.

    Article  Google Scholar 

  37. Eichler K, Zangos S, Mack MG, Hammerstingl R, Gruber-Rouh T, Gallus C, et al. First human study in treatment of unresectable liver metastases from colorectal cancer with irinotecan-loaded beads (DEBIRI). Int J Oncol. 2012;41(4):1213–20.

    PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflict of Interest

All authors declare that they have no conflicts of interest.

Statement of Informed Consent

Statement of informed consent does not apply to this article.

Statement of Human and Animal Rights

Statement of human and animal rights does not apply to this article.

Author information

Authors and Affiliations

  1. Department of Radiology and Nuclear Medicine, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway

    Ulrik Carling, Eric J. Dorenberg & Dag Tallak Berntzen

  2. Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway

    Sven-Petter Haugvik & Bård Røsok

  3. Department of Ophthalmology, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway

    Nils Andreas Eide

  4. The Intervention Centre, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway

    Bjørn Edwin

  5. Department of Oncology, Oslo University Hospital, Postbox 4950, 0424, Oslo, Norway

    Svein Dueland

Authors
  1. Ulrik Carling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric J. Dorenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sven-Petter Haugvik
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nils Andreas Eide
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dag Tallak Berntzen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bjørn Edwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Svein Dueland
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Bård Røsok
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ulrik Carling.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Carling, U., Dorenberg, E.J., Haugvik, SP. et al. Transarterial Chemoembolization of Liver Metastases from Uveal Melanoma Using Irinotecan-Loaded Beads: Treatment Response and Complications. Cardiovasc Intervent Radiol 38, 1532–1541 (2015). https://doi.org/10.1007/s00270-015-1093-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-015-1093-4

Keywords

Search

Navigation